GMAB

Business Context and Reporting Period

Company: Genmab A/S (Genmab)
Filing Type: Annual Report on Form 20-F
Reporting Period: Fiscal year ended December 31, 2024
Accounting Standards: International Financial Reporting Standards (IFRS)
Reporting Currency: Danish Kroner (DKK)

Genmab is an international biotechnology company focused on developing antibody-based products for cancer and other serious diseases. The company operates a hybrid business model, generating revenue through royalties and milestones from collaboration partners (primarily Johnson & Johnson) and through the commercialization of proprietary products (e.g., EPKINLY, Tivdak). In 2024, Genmab completed the acquisition of ProfoundBio, Inc., adding ADC technology and the Rina-S candidate to its pipeline.

Key Financial Metrics

Note: Specific revenue, profit, and cash flow figures for the fiscal year 2024 are incorporated by reference to the Genmab A/S Statutory Annual Report 2024 (Exhibit 99.1(a)) and are not explicitly detailed in the provided text. The following metrics are derived from the text where available.

• Revenue Composition: The substantial majority of revenue comes from royalties on sales of DARZALEX (daratumumab). In 2024, royalties and milestone payments from Johnson & Johnson (J&J) accounted for 65% of total revenue.
• Outstanding Shares: 66,187,186 Ordinary Shares (including shares underlying ADSs) and 62,804,560 American Depositary Shares (ADSs) as of the close of the period.
• Employee Count: 2,682 employees as of December 31, 2024 (up from 548 in 2019).
• Capital Allocation: Executed share buy-back programs in 2024, repurchasing 2,011,853 shares. The March 2024 program utilized approximately DKK 3.5 billion.
• Debt and Liquidity: The company maintains an undrawn unsecured three-year revolving credit facility. Specific debt balances and liquidity figures are referenced in the Audited Financial Statements but not provided in the text.

Material Changes and Operational Highlights

• Acquisition of ProfoundBio: Completed on May 21, 2024, for USD 1.72 billion (DKK 11.8 billion). This acquisition added the Rina-S ADC candidate and proprietary ADC technology platforms to Genmab's portfolio.
• Commercialization Shifts:
  • Tivdak (tisotumab vedotin): Effective January 1, 2025, Genmab assumed sole responsibility for development and commercialization in Europe and most global regions (excluding U.S. and China), previously shared with Pfizer.
  • EPKINLY (epcoritamab): Genmab and AbbVie continue co-commercialization in the U.S. and Japan. Genmab records net product sales as the principal in these territories.
• Regulatory Milestones:
  • Tivdak: Received full FDA approval in April 2024 for recurrent or metastatic cervical cancer, converting from accelerated approval.
  • EPKINLY: Received FDA accelerated approval in June 2024 for relapsed/refractory follicular lymphoma (R/R FL).
  • Rina-S: Granted Fast Track Designation (FTD) by the FDA in January 2024 for platinum-resistant ovarian cancer.
• Portfolio Optimization: Discontinued several programs in 2024 (GEN1047, GEN3017, GEN1056, and GEN1053) following strategic re-evaluation. BioNTech opted out of further development of acasunlimab, leaving Genmab with sole responsibility.

Outlook, Risks, and Contingencies

Guidance and Outlook

Genmab expects royalties from DARZALEX to begin declining materially in 2029 following the expiration of U.S. patent rights. The company is actively advancing proprietary late-stage programs (epcoritamab, Rina-S, acasunlimab) to diversify revenue streams. Management anticipates increased research and development expenses as proprietary candidates advance toward commercialization.

Key Risks

• Patent Expiration: DARZALEX royalties are time-limited. U.S., European, and Japanese patents expire in 2029, 2031, and 2030, respectively. Biosimilar competition is a significant threat.
• Collaboration Dependence: Revenue is heavily dependent on J&J's commercial success with DARZALEX and other partnered products. Termination of key collaborations could materially harm financial results.
• Legal Proceedings:
  • J&J Arbitration: Concluded in January 2024 with Genmab's claims regarding subcutaneous daratumumab royalties denied.
  • Chugai Litigation: In 2024, Chugai filed a lawsuit in Japan alleging EPKINLY infringes two Japanese patents. Genmab intends to vigorously defend against this.
• Regulatory and Clinical Risks: High risk of failure in clinical trials, potential for adverse events, and uncertainty regarding regulatory approvals in various jurisdictions.

Investor Verification Checklist

• Financial Statements: Review the full Audited Financial Statements (incorporated by reference) for specific revenue, net income, and cash flow figures for 2024.
• DARZALEX Sales Trends: Monitor J&J's quarterly sales reports for daratumumab to assess the trajectory of Genmab's primary revenue stream ahead of 2029 patent expirations.
• ProfoundBio Integration: Verify the progress of Rina-S Phase III trials and the integration of ADC technology post-acquisition.
• Legal Status: Track the status of the Chugai patent infringement lawsuit in Japan regarding EPKINLY.
• Commercialization Transition: Assess the impact of Genmab taking sole commercial responsibility for Tivdak in Europe and other regions starting January 2025.
• Internal Controls: Note the remediation of the previously reported material weakness regarding royalty revenue accounting, which was deemed effective as of December 31, 2024.